33 citations
,
January 2009 in “Contraception” This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.
25 citations
,
October 2019 in “Journal of Endocrinological Investigation” This study reported that both drospirenone and chlormadinone acetate oral contraceptives had similar beneficial effects on clinical, metabolic, and hormonal parameters in women with polycystic ovary syndrome over six months.
13 citations
,
September 2011 in “American Journal of Clinical Dermatology” This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.
6 citations
,
March 2012 in “Journal of the European Academy of Dermatology and Venereology” This study found that 12 cycles of chlormadinone acetate in hormonal contraceptives significantly improved oily skin and hair quality, enhancing psychosocial well-being in healthy women.
4 citations
,
September 2011 in “American Journal of Clinical Dermatology” This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.